HU
HUMDF.US Hua Medicine (Shanghai) Ltd
- Market cap
- USD 303M
- P/E
- -
- P/B
- 2.04x
- ROE
- -12.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is HUMDF.US undervalued?
Graham numberThe Graham number of Hua Medicine (Shanghai) Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hua Medicine (Shanghai) Ltd fundamental analysis
No fundamental analysis for Hua Medicine (Shanghai) Ltd yet.
Hua Medicine (Shanghai) Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hua Medicine (Shanghai) Ltd
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insuli…
Full company profileHua Medicine (Shanghai) Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hua Medicine (Shanghai) Ltd annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 595K | 10.5M | 9.13M | 22.3M | 8.66M | 0.00 | 17.6M | 76.6M | 256M | 480M | 1.49B |
| Gross Profit | 595K | 10.5M | 9.13M | 22.3M | 8.66M | -4.93M | 7.69M | 37.4M | 125M | 273M | 924M |
| Operating Income | -94.2M | -146M | -399M | -423M | -352M | -321M | -267M | -289M | -353M | -141M | -105M |
| EBITDA | -93.4M | -145M | -359M | -436M | -326M | -290M | -168M | -167M | -207M | -109M | -56.2M |
| Net Income | -361M | -273M | -3.60B | -428M | -396M | -331M | -204M | -211M | -250M | 1.08B | -119M |
| EPS | -0.34 | -0.26 | -10 | -0.45 | -0.42 | -0.35 | -0.21 | -0.22 | -0.25 | 1.07 | -0.12 |
| Balance Sheet | |||||||||||
| Total Assets | 227M | 246M | 1.49B | 1.25B | 1.20B | 904M | 1.12B | 1.73B | 1.53B | 1.47B | 1.52B |
| Total Liabilities | 893M | 1.19B | 86.8M | 194M | 466M | 453M | 842M | 1.62B | 1.66B | 464M | 522M |
| Shareholders' Equity | -670M | -954M | 1.40B | 1.06B | 732M | 450M | 280M | 101M | -135M | 1.01B | 993M |
| Cash & Short-term Investments | 223M | 189M | 1.44B | 1.11B | 1.03B | 675M | 491M | 1.46B | 1.14B | 1.09B | 1.07B |
| Total Debt | 855M | 1.14B | - | 90.0M | 80.7M | 71.5M | 97.6M | 168M | 300M | 302M | 354M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -76.1M | -199M | -269M | -342M | -20.9M | -273M | -230M | 889M | -418M | -52.2M | -251M |
| Capital Expenditure | 647K | 2.42M | 5.10M | 10.3M | 25.7M | 66.9M | 27.5M | 9.84M | 3.86M | 7.55M | 15.0M |
| Free Cash Flow | -76.7M | -201M | -275M | -352M | -46.6M | -340M | -258M | 880M | -422M | -59.7M | -266M |
| Ratios | |||||||||||
| ROE | - | - | -256.7% | -40.3% | -54.1% | -73.5% | -72.9% | -208.8% | - | 107.0% | -12.0% |
| ROA | -159.4% | -111.0% | -241.8% | -34.1% | -33.1% | -36.6% | -18.2% | -12.2% | -16.4% | 73.3% | -7.9% |
| Net Profit Margin | -60,727.4% | -2,593.6% | -39,464.6% | -1,922.5% | -4,575.6% | - | -1,157.8% | -275.7% | -97.8% | 224.4% | -8.0% |
| Debt to Equity | - | - | - | 0.08x | 0.11x | 0.16x | 0.35x | 1.66x | - | 0.30x | 0.36x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hua Medicine (Shanghai) Ltd dividends
Hua Medicine (Shanghai) Ltd has not paid dividends in the last 9 fiscal years.
Who owns Hua Medicine (Shanghai) Ltd
- Insiders 13.25%
- Institutions 22.76%
- Public & others 63.99%
- Shares outstanding 999M
- Free float 663M
Hua Medicine (Shanghai) Ltd company profile
- Company name
- Hua Medicine (Shanghai) Ltd
- Ticker
- HUMDF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 424
- Fiscal year end
- December
- Address
- Hua Medicine, Building 2, Lane 36, Shanghai, China, 201203
- Phone
- 86 21 3810 1800
- Website
- huamedicine.com
About Hua Medicine (Shanghai) Ltd
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) inhibitor and GK NAM for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and Dorzagliatin for the treatment of T2D-Drug Naïve, T2D-Metformin Tolerated, RWE study for Diabetes Remission, MODY-2, Diabetes prevention IGT2NGT, Frailty, Early AD, and CFRD. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is headquartered in Shanghai, China.
Hua Medicine (Shanghai) Ltd management
9- Dr. Li Chen Ph.D.Founder, CEO, Member of Portfolio Advisory Board & Executive Director · born 1963
- Dr. Yi Zhang M.D., Ph.D.Senior VP of Pharma Development, Chief Medical Officer ? China and Executive Director · born 1975
- Mr. Chien Cheng Lin J.D.Executive VP, Chief Strategy Officer & Executive Director · born 1971
- Dr. Fuxing Tang Ph.D.CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA · born 1967
- Dr. Changhong Li Ph.D.Chief Scientific Officer · born 1970
- Mr. Chengde WangHead of IR · born 1948
- Mr. Yu LuVice President of Sales & Marketing · born 1975
- Mr. Ying Xie M.B.A.VP of Quality Assurance Division & Chief Quality Officer · born 1980
- Ms. Nelly Au-YeungCompany Secretary